Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes
Pancreatic cancer is the seventh leading cause of cancer-related mortality in both sexes across the globe. It is associated with extremely poor prognosis and remains a critical burden worldwide due to its low survival rates. Histologically, pancreatic ductal adenocarcinoma (PDAC) accounts for 80% of...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/12/3196 |
| _version_ | 1797461298310545408 |
|---|---|
| author | Liia Akhuba Zhanna Tigai Dmitrii Shek |
| author_facet | Liia Akhuba Zhanna Tigai Dmitrii Shek |
| author_sort | Liia Akhuba |
| collection | DOAJ |
| description | Pancreatic cancer is the seventh leading cause of cancer-related mortality in both sexes across the globe. It is associated with extremely poor prognosis and remains a critical burden worldwide due to its low survival rates. Histologically, pancreatic ductal adenocarcinoma (PDAC) accounts for 80% of all pancreatic cancers; the majority of which are diagnosed at advanced stages, which makes them ineligible for curative surgery. Conventional chemotherapy provides a five-year overall survival rate of less than 8% forcing scientists and clinicians to search for better treatment strategies. Recent discoveries in cancer immunology have resulted in the incorporation of immunotherapeutic strategies for cancer treatment. Particularly, immune-checkpoint inhibitors, adoptive cell therapies and cancer vaccines have already shifted guidelines for some malignancies, although their efficacy in PDAC has yet to be elucidated. In this review, we summarize the existing clinical data on immunotherapy clinical outcomes in patients with advanced or metastatic PDAC. |
| first_indexed | 2024-03-09T17:18:16Z |
| format | Article |
| id | doaj.art-743291ab345a4d62adc379ca968f69fd |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T17:18:16Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-743291ab345a4d62adc379ca968f69fd2023-11-24T13:28:31ZengMDPI AGBiomedicines2227-90592022-12-011012319610.3390/biomedicines10123196Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical OutcomesLiia Akhuba0Zhanna Tigai1Dmitrii Shek2Blacktown Mt Druitt Hospital, Sydney, NSW 2148, AustraliaAccreditation Centre, RUDN University, Moscow 117198, RussiaBlacktown Mt Druitt Hospital, Sydney, NSW 2148, AustraliaPancreatic cancer is the seventh leading cause of cancer-related mortality in both sexes across the globe. It is associated with extremely poor prognosis and remains a critical burden worldwide due to its low survival rates. Histologically, pancreatic ductal adenocarcinoma (PDAC) accounts for 80% of all pancreatic cancers; the majority of which are diagnosed at advanced stages, which makes them ineligible for curative surgery. Conventional chemotherapy provides a five-year overall survival rate of less than 8% forcing scientists and clinicians to search for better treatment strategies. Recent discoveries in cancer immunology have resulted in the incorporation of immunotherapeutic strategies for cancer treatment. Particularly, immune-checkpoint inhibitors, adoptive cell therapies and cancer vaccines have already shifted guidelines for some malignancies, although their efficacy in PDAC has yet to be elucidated. In this review, we summarize the existing clinical data on immunotherapy clinical outcomes in patients with advanced or metastatic PDAC.https://www.mdpi.com/2227-9059/10/12/3196pancreatic cancerimmunotherapyimmune-checkpoint inhibitorsCAR T-cell therapycancer vaccines |
| spellingShingle | Liia Akhuba Zhanna Tigai Dmitrii Shek Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes Biomedicines pancreatic cancer immunotherapy immune-checkpoint inhibitors CAR T-cell therapy cancer vaccines |
| title | Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes |
| title_full | Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes |
| title_fullStr | Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes |
| title_full_unstemmed | Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes |
| title_short | Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes |
| title_sort | where do we stand with immunotherapy for advanced pancreatic ductal adenocarcinoma a synopsis of clinical outcomes |
| topic | pancreatic cancer immunotherapy immune-checkpoint inhibitors CAR T-cell therapy cancer vaccines |
| url | https://www.mdpi.com/2227-9059/10/12/3196 |
| work_keys_str_mv | AT liiaakhuba wheredowestandwithimmunotherapyforadvancedpancreaticductaladenocarcinomaasynopsisofclinicaloutcomes AT zhannatigai wheredowestandwithimmunotherapyforadvancedpancreaticductaladenocarcinomaasynopsisofclinicaloutcomes AT dmitriishek wheredowestandwithimmunotherapyforadvancedpancreaticductaladenocarcinomaasynopsisofclinicaloutcomes |